Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of [14C]-INDV-2000 in Healthy Men
NCT05974046Phase 1Completed
- Sponsor
- Indivior
- Start
- Jul 2023
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C4X3256 in opioid use disorder (OUD), sponsored by Indivior. Primary endpoints: Percent of Radioactive Dose Excreted in the Urine, Feces, and Urine+Feces, Cumulative Percent of Radioactive Dose Excreted in the Urine, Feces, and Urine+Feces and 9 more. Started Jul 2023; status: completed.
02
Drugs
C4X3256
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05974046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05974046.